MSCs for treatment of stroke

MSC therapies include cell delivery via intravenous, inta-arterial, or intracerebral injections. To attain maximum cell concentration in the area supplied by a particular artery, intra-arterial infusion is very effective, yet it is invasive, as at least minor surgery is needed for access, which may cause blockage of local capillaries with transplanted cells.

For intracerebral injections anaesthesia and surgery are also required and the MSCs are transplanted directly into the damaged area of the brain, which is invasive and can interrupt the blood brain barrier (BBB). For clinical use, it is best that an open blood brain barrier and access to penubra are available for intravenous delivery of MSCs to occur, which makes it necessary to control the timing of therapy. (Borlongan et al., 2011). Intra-venous stem cell administration is considered safer, than site directed transplantation, because it is widely available, multiple doses of stem cells, even high doses, can be injected for a long time at certain intervals and no contraindications, due to absence of surgical intervention have been identified. Nevertheless, not all IV injected cells transmigrate and reach the site of injury, but only a small number of them.

Despite its limitations, many studies have demonstrated that intracerebral MSC delivery showed effective engraftment, especially in inflammatory conditions. MSCs transplanted into the brain have been demonstrated to promote functional recovery by producing trophic factors that induce survival and regeneration of host neurons, as well as alter the gap junction coupling between astrocytes, allowing them to respond more effectively to damage (Li and Chopp, 2009).

The primary trophic property of MSCs is the secretion of growth factors and other chemokines to induce cell proliferation. MSCs express mitogenic proteins such as: transforming growth factor-alpha (TGF-α), TGF-β, hepatocyte growth factor (HGF), epithelial growth factor (EGF), basic fibroblast growth factor (FGF-2) and insulin-like growth factor-1 (IGF-1). (Table 1)(Murphy et al., 2013).

Table 1 Trophic, immunomodulatory and antimicrobial factors sectered by activated MSCs (Murphy et al., 2013).

Trophic effects	Immunomodulatory effects	Antimicrobial effects
Anti-scarring: KGF, SDF-1, Mip-1α and 1β Anti-Apoptotic: STC-1, SFRP2, TGF-β1, VEGF, HGF Angiogenic: TGF-β1, VEGF Mitogenic: TGF-β, TGF-α, HGF, IGF-1, FGF-2, EGF.	IL-6, IL-8, IL-10, IL-1RA, PGE2, IDO, HGF, TSG-6, STNF-R, NO, sHLA-GS, TGF-β1	LL-37, IDO

Benefits of MSCs in the ischemic brain include: transdifferentiation, induction of neurogenesis and angiogenesis, neuroprotection, and activation of endogenous neurorestorative processes, as well as decrease apoptosis, reduce levels of free radicals, encourage synaptic connection from damaged neurons and regulate inflammation, primarily through paracrine actions(Figure 9) (Nanette Joyce et al, 2010).

Parekkadan et al.,(2010) and Chen et al., (2001) Conclude that although the benefits of MSCs are undeniable, the homing of MSC to brain infarcted sites is far from ideal.

Figure 9 Potential neuroprotective and neurorestorative effects of mesenchymal stem cells. (Castillo-Melendez et al., 2013)  

Дата добавления: 2015-10-23